GlobeNewswire

Lung Ambition Alliance launches with goal to double five-year survival in lung cancer by 2025

Share

Collaboration prioritizes scientific innovation and social change to one day eliminate lung cancer as a cause of death

LONDON, July 08, 2019 (GLOBE NEWSWIRE) -- Today, the International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (GLCC) and AstraZeneca announced the Lung Ambition Alliance, a new partnership with a bold ambition to eliminate lung cancer as a cause of death. The first goal of the Alliance will be to double five-year survival for patients with lung cancer by 2025.

Every 18 seconds, a life is lost to lung cancer.1 In 2018 alone, approximately 1.8 million people died from the disease.1 Forty percent of patients are diagnosed when the cancer has already spread beyond the lung and their prognosis has worsened.2 Currently, only one in five lung cancer patients are alive five years after diagnosis.3

Jesme Fox, Secretary for GLCC, said: “ The Lung Ambition Alliance has been created at a pivotal time for lung cancer. Scientific advances are enabling new possibilities to transform diagnosis, treatment and the management of the disease. Yet barriers remain to improving and accelerating care. As members of the lung cancer community, we have a responsibility to come together with urgency to advocate for and advance the best solutions for patients.”

The Alliance represents a broad range of complementary expertise, including research and education (IASLC), diagnostics (Guardant Health), patient advocacy (GLCC), and medicines research and development (AstraZeneca).

The founding partners have identified three priorities: increasing screening and early diagnosis, delivering innovative medicine and improving the quality of care for people with lung cancer. Initial projects being accelerated through the Alliance include:

  1. T he Early Lung Imaging Confederation (ELIC) is a new, cloud-based worldwide screening database designed to accelerate improvements in the multidisciplinary detection and management of early-stage lung cancer. The project capitalizes on growing evidence that CT screening can lead to reduced mortality.4 This collection of images and data can be used to build better risk models, as well as analysis and detection tools, while serving as a global standard for data quality. In a future phase, artificial intelligence (AI) may be applied to further improve the reliability of clinical decision-support with CT screening. The Alliance will contribute to building out the image bank for this IASLC-owned project, first piloted in late 2018, and will assist in measuring patient outcomes to be assessed at various points in the patient journey (including initial scan, initial treatment, and follow up).

Giorgio Scagliotti, President of IASLC said: “Effective screening is key to finding and diagnosing lung cancer and other thoracic malignancies early, which can translate to more options and longer survival. Yet screening is underutilized around the world for several reasons. The application of quantitative imaging approaches like ELIC could improve the accuracy and the efficiency of lung cancer screening. Our platform is poised to become an important global resource for lung cancer researchers and care teams looking to expand their knowledge. The Lung Ambition Alliance is providing the focus, expertise, and resources needed to dramatically accelerate the expansion of our data catalogue.”

  1. The Major Pathologic Response Project is a collection of clinical trial data and research that can be used to validate surrogate endpoints and identify predictive biomarkers, which may enable better targeting of tumor characteristics. Its aims to accelerate development of the next generation of targeted treatments and drive the shift to earlier intervention when there is greater potential for a cure.5 The Alliance is assisting in the pooling of data from cooperative groups and across pharmaceutical industry trials, which can be used with health authorities around the world when discussing pivotal trial data.

AmirAli Talasaz, President and Chief Operating Officer, Guardant Health said: “Precision medicine is improving prognosis for some lung cancer patients and delivering better clinical outcomes. We believe precision medicine approaches can be even more effective when utilized earlier in the course of the disease, or immediately upon detection of relapse. The Major Pathologic Response Project will help accelerate development of potentially curative treatment options, with the identification of surrogate endpoints that can be used to quicken clinical trials and novel diagnostic approaches – like the detection of circulating tumor DNA in blood samples – to identify patients with a poor prognosis, allow routine assessment of therapeutic response, and promote ongoing monitoring of cancer remission.”

  1. Initiatives in Lung Cancer Care (ILC2) is an open call anticipated to launch in late 2019, inviting local patient organizations around the world to develop and submit pilot projects that can potentially transform patient care and improve survival at the local level. It aims to help the local lung cancer community benefit from multidisciplinary best practices, educate patients about their options and provide quality-of-life support to patients throughout and following treatment. A Lung Ambition Alliance committee will evaluate and select submissions that have met the selection criteria for funding.

Patrick Connor, VP and Global Franchise Head, Tumor Drivers and Resistance Mechanisms, AstraZeneca, said: “Lung cancer is a highly personal disease, and care approaches can vary widely around the world. In order to reach our survival goal, we must encourage initiatives that address barriers at the country level and increase screening and early diagnosis, aid the development of innovative medicine and improve quality care. By joining together with partners who have broad global networks and distinct but complementary areas of focus in lung cancer, we are better positioned to address issues those patients face.”

The Alliance will sponsor an international survey, led by Ipsos MORI, to identify local barriers that need priority focus. Results, expected in the fall of 2019, will be used to further refine and shape the priorities of the Lung Ambition Alliance. Information about the survey, and how the community can share their perspectives, can be found at LungAmbitionAlliance.org. 

About the Lung Ambition Alliance

The Lung Ambition Alliance is a flagship partnership of diverse organizations united in the quest to eliminate lung cancer as a cause of death. The Alliance aims to accelerate progress and bring meaningful change for lung cancer patients by amplifying the expertise of each partner and prioritizing meaningful projects with potential to further its goal. The founding partners – the International Association for the Study of Lung Cancer (IASLC), Guardant Health, the Global Lung Cancer Coalition (GLCC) and AstraZeneca – will explore and overcome barriers to screening and early diagnosis, the development of innovative medicine and quality care, and pursue an ambitious vision for the future in lung cancer that starts with doubling five-year survival by 2025.

For more information, visit www.lungambitionalliance.org.

About the Founding Partners  

  • The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer and other thoracic malignancies, with a global network of more than 6,500 lung cancer specialists across all disciplines in over 100 countries.

  • The Global Lung Cancer Coalition is the international voice of lung cancer patients and committed to patient advocacy.

  • Guardant Health is an innovative diagnostics company with a vision to enable earlier detection through access to molecular information in the blood.

  • AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialization of prescription medicines. 

CONTACTS:

Jennifer Corrigan
BursonRx
Jennifer.Corrigan@bursonrx.com
+1-347-366-1444

Emma Barrow
GCI Health
Emma.Barrow@gcihealth.com
+44-207-300-6114

Accelerating Advances for People with Lung Cancer.

References
______________________

1 World Health Organization. International Agency for Research on Cancer. Fact Sheet – Lung Cancer. Available at http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf. Accessed May 2019
2 EpiCast Report: NSCLC Epidemiology Forecast to 2025. GlobalData. 2016.
3 Cancer.Net. Lung Cancer - Non-Small Cell - Statistics. Available at www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics. Accessed May 2019
4 IASLC. IASLC Successfully Pilots Early Lung Imaging Confederation Project. Available at https://www.iaslc.org/news/iaslc-successfully-pilots-early-lung-imaging-confederation-project-0. Accessed May 2019
5 IASLC. IASLC Pathology Committee. Available at https://www.iaslc.org/research-education/iaslc-pathology-committee. Accessed May 2019

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Bombardier’s Multi-Award-Winning Global 7500 Jet Reaches New Heights in the Heart of the Swiss Alps15.7.2019 19:00:00 CESTPress release

Global 7500 aircraft is the most spacious purpose-built business jet to operate out of Gstaad’s Saanen airport in Switzerland, where it was on display earlier this month before flying to Dubai, performing another exceptional long-range mission Mission highlights the Global family’s advanced wing design, which enables them to access challenging airfields with short runways in hot temperatures and/or high altitude locations, giving passengers direct access to the heart of the Swiss Alps all year round The Aviation Week Grand Laureate Global 7500 aircraft, also recently recognized as Business Jet of the Year in Robb Report’s Best of the Best 2019, offers Bombardier’s signature smooth ride and a spaciousness that is unique among business jets Bombardier’s Challenger 350 aircraft, also recognized as the Best of the Best Super Mid-size Aircraft by Robb Report, joined the Global 7500 jet on display in Gstaad and achieved a speed record, reaching Malaga in 2 hours and 4 minutes MONTREAL, July

Brookfield Asset Management 2019 Second Quarter Results Conference Call and Webcast15.7.2019 18:27:00 CESTPress release

Date: Thursday, August 8, 2019 Time: 11:00 a.m. (Eastern Time) BROOKFIELD, NEWS, July 15, 2019 (GLOBE NEWSWIRE) -- Brookfield Asset Management (NYSE:BAM)(TSX:BAM.A)(EURONEXT AMSTERDAM:BAMA): Second Quarter Conference Call You are invited to participate in Brookfield Asset Management’s 2019 Second Quarter Conference Call & Webcast on Thursday, August 8, 2019 at 11:00 a.m. (Eastern Time) to discuss with members of senior management our results and current business initiatives. These results will be released on August 8th before 7:00 a.m. (Eastern Time) and will be available following the release on our website at www.brookfield.com “News – Press Releases.” The Conference Call will also be Webcast live on our website, where it will be archived for future reference. To participate in the Conference Call, please dial 1-866-688-9425 toll free in North America, or for overseas calls please dial 1-409-216-0815 (Conference ID: 8258617) at approximately 10:50 a.m. The Conference Call will also b

Virtusa Achieves AWS Life Sciences Competency Status15.7.2019 16:01:00 CESTPress release

Virtusa joins a group of AWS Partner Network members helping Life Sciences providers to deliver superior patient outcomes SOUTHBOROUGH, Mass., July 15, 2019 (GLOBE NEWSWIRE) -- Virtusa Corporation (NASDAQ GS: VRTU), a global provider of digital strategy, digital engineering, and IT outsourcing services that accelerates business outcomes for its clients, announced today that it has achieved Amazon Web Services (AWS) Life Sciences Competency status. This designation recognizes Virtusa for providing deep expertise in building Life Sciences solutions on AWS to help customers conduct drug discovery, manage clinical trials, engage in manufacturing and distribution activities, conduct research and development of novel genetic-based treatments and companion diagnostics. Achieving the AWS Life Sciences Competency differentiates Virtusa as an AWS Partner Network (APN) member that has demonstrated relevant technical proficiency and proven customer success, delivering solutions seamlessly on AWS.

LGC Capital, Ltd., announces Trichomed received its cultivation license from Health Canada for its new cannabis facility in Brownsburg, Quebec15.7.2019 15:28:00 CESTPress release

MONTREAL, July 15, 2019 (GLOBE NEWSWIRE) -- LGC Capital Ltd. (TSX-V: LG / OTCQB: LGGCF) LGC Capital Ltd. (“LGC” or the “Company”), announces that Health Canada, on July 12th, awarded Trichomed Corporation (Trichomed), its long awaited license to cultivate cannabis seeds and plants at its newly constructed facility in Brownsburg, Quebec. As per the terms of its agreement with Trichomed, LGC is, now entitled to convert the first ranking secured loan it provided to Trichomed in December 2017 into a 49% direct equity interest, and a five percent (5%) royalty of Trichomed’s net sales of cannabis and cannabis-related prodcuts which covers actual sales less any arm’s length third-party discounts, merchandise returns and rebates. In addition as per the agreement, LGC is entitled to representation on Trichomed’s board. For further information, please contact: John McMullen, President Tel: (416) 803-0698 john@lgc-capital.com Mark Shinners, Chief Financial Officer Tel: +44 7827 960971 mark@lgc-ca

WSO2 Introduces WSO2 API Microgateway 3.0 to Simplify Creating, Deploying and Securing APIs in Microservice Environments15.7.2019 15:00:00 CESTPress release

Newest release of the fully open source, cloud-native WSO2 API Microgateway adds new features to facilitate development and management while enabling greater scalability Mountain View, CA and Portland, OR, July 15, 2019 (GLOBE NEWSWIRE) -- Microservices are rapidly becoming the de facto standard for modern software development. As a result, thousands of microservices are replacing hundreds of enterprise apps within an organization—driving exponential growth in the number of programmable endpoints handled by APIs. To simplify the process of creating, deploying and securing APIs within distributed microservices architectures, WSO2 has introduced several new features in version 3.0 of its fully open source WSO2 API Microgateway. The availability of WSO2 API Microgateway 3.0 is being announced in conjunction with OSCON 2019, the O’Reilly Open Source Software Conference. WSO2, the world’s #1 open source integration vendor and an OSCON sponsor, will offer demos of the latest WSO2 API Microga

WillScot to Participate at the Jefferies Industrials Conference15.7.2019 15:00:00 CESTPress release

BALTIMORE, July 15, 2019 (GLOBE NEWSWIRE) -- WillScot Corporation (“WillScot”) (Nasdaq: WSC), the specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that Brad Soultz, President and Chief Executive Officer, and Tim Boswell, Chief Financial Officer, will present at the Jefferies Industrials Conference in New York, on Wednesday, August 7, 2019. The presentation will take place at 11:30 a.m. EDT. About WillScot Corporation Headquartered in Baltimore, Maryland, WillScot is the public holding company for the Williams Scotsman family of companies. WillScot trades on the Nasdaq stock exchange under the ticker symbol "WSC," and is the specialty rental services market leader providing innovative modular space and portable storage solutions across North America. WillScot is the modular space supplier of choice for the construction, education, health care, government, retail, commercial, transportation, se